Preclinical pharmacokinetics and pharmacodynamic target of SCY-078, a first-in-class orally active antifungal glucan synthesis inhibitor, in murine models of disseminated candidiasis

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 4, 2017, Pages

  Wring, Stephen A ^a   Randolph, Ryan ^a   Park, Seong Hee ^a   Abruzzo, George ^b   Chen, Qing ^b   Flattery, Amy ^b   Garrett, Graig ^b   Peel, Michael ^a   Outcalt, Russell ^a   Powell, Kendall ^a   Trucksis, Michelle ^b   Angulo, David ^a   Borroto Esoda, Katyna ^a  

^a Scynexis   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Candidemia; Fungal disease; Pharmacokinetics; SCY 078

Indexed keywords

ANTIFUNGAL AGENT; CASPOFUNGIN; GLUCAN; MK 3118; UNCLASSIFIED DRUG; CARBOXYLIC ACID; PHENANTHRENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; CACO-2 CELL LINE; CANDIDA ALBICANS; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG PENETRATION; DRUG SOLUBILITY; DRUG TARGETING; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INVASIVE CANDIDIASIS; MALE; METABOLIC STABILITY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRECLINICAL STUDY; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; ANIMAL; ANTAGONISTS AND INHIBITORS; AREA UNDER THE CURVE; BIOAVAILABILITY; BIOSYNTHESIS; BLOOD; CANDIDIASIS; CELL WALL; DISEASE MODEL; DOG; DOSE CALCULATION; DRUG ADMINISTRATION; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HUMAN; LIVER MICROSOME; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; SYNTHESIS;

ANIMALS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CANDIDA ALBICANS; CANDIDIASIS; CARBOXYLIC ACIDS; CELL WALL; DISEASE MODELS, ANIMAL; DOGS; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; FEMALE; GLUCANS; HUMANS; MALE; MICE; MICROBIAL SENSITIVITY TESTS; MICROSOMES, LIVER; PHENANTHRENES; RATS;

EID: 85017012850     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02068-16     Document Type: Article

References (39)

1. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky- Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD. 2016. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 62: 409-417. https://doi.org/10.1093/cid/civ1194.
2. Pfaller MA, Messer SA, Motyl MR, Jones RN, Castanheira M. 2013. Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST). J Antimicrob Chemother 68: 858-863. https://doi.org/10.1093/jac/dks466.
3. Pfaller MA, Messer SA, Motyl MR, Jones RN, Castanheira M. 2013. In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods. Antimicrob Agents Chemother 57: 1065-1068. https://doi.org/10.1128/AAC.01588-12.
4. Jim?ez-Ortigosa C, Paderu P, Motyl MR, Perlin DS. 2014. Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida species and Aspergillus species isolates. Antimicrob Agents Chemother 58: 1248-1251. https://doi.org/10.1128/AAC.02145-13.
5. Trucksis M, Garrett G, Bautmans A, Heirman I, Laethem M, Comisar WA, Maganti L, Bi S, Iwamoto M, O'Mara E, Wagner JA, Depre M, de Hoon J. 2011. A phase I multiple-rising dose study evaluating safety, tolerability, and pharmacokinetics of MK-3118, oral glucan synthase inhibitor in healthy volunteers, abstr F1-1390. Abstr 51st Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
6. Lepak AJ, Marchillo K, Andes DR. 2015. Pharmacokinetic target evaluation of a novel oral glucan synthesis inhibitor, SCY-078 (MK3118), using an in vivo murine invasive candidiasis model. Antimicrob Agents Chemother 59: 1265-1272. https://doi.org/10.1128/AAC.04445-14.
7. Wring S, Abruzzo G, Borroto-Esoda K, Chen Q, Flattery A, Garrett G, Trucksis M, Ribeill Y. 2014. Exposure target for the first-in-class, orally active, glucan synthesis inhibitor SCY-078 (MK-3118) in disseminated candidiasis. Abstr 54th Intersci Conf Antimicrob Agents Chemother, abstr F-1595.
8. Abruzzo GK, Gill CJ, Flattery AM, Kong L, Leighton C, Smith JG, Pikounis VB, Bartizal K, Rosen H. 2000. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob Agents Chemother 44: 2310-2318. https://doi.org/10.1128/AAC.44.9.2310-2318.2000.
9. Artursson P, Palm K, Luthman K. 2001. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 46: 27- 43. https://doi.org/10.1016/S0169-409X(00)00128-9.
10. Houston JB. 1994. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47: 1469 -1479. https://doi.org/10.1016/0006-2952(94)90520-7.
11. Pel?z F, Cabello A, Platas G, D?z MT, del Gonz?ez VA, Basilio A, Mart? I, Vicente F, Bills GE, Giacobbe RA, Schwartz RE, Onish JC, Meinz MS, Abruzzo GK, Flattery AM, Kong L, Kurtz MB. 2000. The discovery of enfumafungin, a novel anti-fungal compound produced by an endophytic Hormonema species biological activity and taxonomy of the producing organisms. Syst Appl Microbiol 23: 333-343. https://doi.org/10.1016/S0723-2020(00)80062-4.
12. Heasley BH, Pacofsky GJ, Mamai A, Liu H, Nelson K, Coti G, Peel MR, Balkovec JM, Greenlee ML, Liberator P, Meng D, Parker DL, Wilkening RR, Apgar JM, Racine F, Hsu MJ, Giacobbe RA, Kahn JN. 2012. Synthesis and biological evaluation of antifungal derivatives of enfumafungin as orally bioavailable inhibitors of -1,3-glucan synthase. Bioorg Med Chem Lett 22: 6811-6816. https://doi.org/10.1016/j.bmcl.2012.05.031.
13. Peel M, Fan W, Mamai A, Hong J, Orr M, Ouvrey G, Perrey D, Liu H, Jones M, Nelson K, Ogbu C, Lee S, Li K, Kirwan R, Noe A, Sligar A, Martensen P, Balkovec J, Greenlee M, Meng D, Parker D, Wildonger K, Abruzzo G, Flattery A, Galgoci A, Giacobbe R, Gill C, Hsu M, Liberator P, Misura A, Nielsen-Kahn J, Powles MA, Racine F, Dragovic J, Habulihaz B. 2010. Enfumafungin derivatives: Orally active glucan synthase inhibitors. Abstr 50th Intersci Conf Antimicrob Agents Chemother, abstr F1-845.
14. Wilkening R, Apgar J, Meng D, Parker D, Greenlee M, Sperbeck D, Wildonger K, Abruzzo G, Flattery A, Galgoci A, Giacobbe R, Gill C, Hsu M, Liberator P, Misura A, Motyl M, Nielsen-Kahn J, Powles MA, Racine F, Dragovic J, Habulihaz B, Fabre E, Fan W, Heasley B, Kirwan R, Lee S, Liu H, Mamai A, Nelson K, Pacofsky G, Peel Balkovec M JM. 2010. Enfumafungin derivatives: Orally active glucan synthase inhibitors. Abstr 50th Intersci Conf Antimicrob Agents Chemother, abstr F1-846.
15. Obach RS. 1999. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27: 1350-1359.
16. Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm Res 10: 1093-1095. https://doi.org/10.1023/A: 1018943613122.
17. Damle B, Stogniew M, Dowell J. 2008. Pharmacokinetics and tissue distribution of anidulafungin in rats. Antimicrob Agents Chemother 52: 2673-2676. https://doi.org/10.1128/AAC.01596-07.
18. Felton T, Troke PF, Hope WW. 2014. Tissue penetration of anti-fungal agents. Clin Microbiol Rev 27: 68-88. https://doi.org/10.1128/CMR .00046-13.
19. Louie A, Deziel M, Liu W, Drusano MF, Gumbo T, Drusano GL. 2005. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: Importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 49: 5058-5068. https://doi.org/10.1128/AAC.49.12.5058-5068.2005.
20. Gumbo T, Drusano GL, Liu W, Ma L, Deziel MR, Drusano MF, Louie A. 2006. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrob Agents Chemother 50: 3695-3700. https://doi.org/10.1128/AAC.00507-06.
21. Hope WW, Drusano GL. 2009. Antifungal pharmacokinetics and pharmacodynamics: Bridging from the bench to bedside. Clin Microbiol Infect 15: 602-612. https://doi.org/10.1111/j.1469-0691.2009.02913.x.
22. Hajdu R, Thompson R, Sundelof JG, Pelak BA, Bouffard FA, Dropinski JF, Kropp H. 1997. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother 41: 2339-2344.
23. Stone JA, Xu X, Winchell GA, Deutsch PJ, Pearson PG, Migoya EM, Mistry GC, Xi L, Miller A, Sandhu P, Singh R, deLuna F, Dilzer SC, Lasseter KC. 2004. Disposition of caspofungin: Role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 48: 815-823. https://doi.org/10.1128/AAC.48.3.815-823.2004.
24. Niwa T, Yokota Y, Tokunaga A, Yamato Y, Kagayama A, Fujiwara T, Hatakeyama J, Anezaki M, Ohtsuka Y, Takagi A. 2004. Tissue distribution after intravenous dosing of micafungin, an antifungal drug, to rats. Biol Pharm Bull 27: 1154-1156. https://doi.org/10.1248/bpb.27.1154.
25. Sandhu P, Xu X, Bondiskey PJ, Balani SK, Morris ML, Tang YS, Miller AR, Pearson PG. 2004. Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys. Antimicrob Agents Chemother 48: 1272-1280. https://doi.org/10.1128/AAC.48.4.1272-1280.2004.
26. Yamato Y, Kaneko H, Hashimoto T, Katashima M, Ishibashi K, Kawamura A, Terakawa M, Kagayama A. 2002. Pharmacokinetics of the anti-fungal drug micafungin in mice, rats and dogs, and its in vitro protein binding and distribution to blood cells. Jpn Chemother 50: 74-79.
27. Van Vianen W, de Marie S, ten Kate MT, Mathot RAA, Bakker- Woudenberg IAJM. 2006. Caspofungin: Antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis. J Antimicrob Chemother 57: 732-740. https://doi.org/10.1093/jac/dkl015.
28. Groll AH, Mickiene D, Petraitiene R, Petraitis V, Lyman CA, Bacher JS, Piscitelli SC, Walsh TJ. 2001. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): Reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother 45: 2845-2855. https://doi.org/10.1128/AAC.45.10.2845-2855.2001.
29. Groll AH, Gullick BM, Petraitiene R, Petraitis V, Candelario M, Piscitelli SC, Walsh TJ. 2001. Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits. Antimicrob Agents Chemother 45: 596-600. https://doi.org/10.1128/AAC.45.2.596-600.2001.
30. Groll AH, Mickiene D, Petraitis V, Petraitiene R, Ibrahim KH, Picitelli SC, Bekersky I, Walsh TJ. 2001. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob Agents Chemother 45: 3322-3327. https://doi.org/10.1128/AAC.45.12.3322-3327.2001.
31. Eschenauer G, DePestel DD, Carver PL. 2007. Comparison of echinocandin antifungals. Ther Clin Risk 3: 71-97. https://doi.org/10.2147/tcrm.2007.3.1.71.
32. Denning DW. 2003. Echinocandin anti-fungal drugs. Lancet 362: 1142-1151. https://doi.org/10.1016/S0140-6736(03)14472-8.
33. Gumbo T, Ikeda F, Louie A. 2007. Glucan synthase inhibitors, p 355-378. In Nightingale CH, Ambrose PG, Drusano GL, Murakawa T (ed), Antimicrobial pharmacodynamics in theory and clinical practice, 2nd ed. CRC Press, New York, NY.
34. Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A. 2010. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother 54: 2497-2506. https://doi.org/10.1128/AAC.01584-09.
35. Andes D. 2006. Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am 20: 679-697. https://doi.org/10.1016/j.idc .2006.06.007.
36. Wiederhold NP, Najvar LK, Bocanegra R, Molina D, Olivo M, Graybill JR. 2007. In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. Antimicrob Agents Chemother 51: 1616-1620. https://doi.org/10.1128/AAC.00105-07.
37. Ernst EJ, Roling EE, Petzold CR, Keele DJ, Klepser ME. 2002. In vitro activity of micafungin (FK-463) against Candida spp.: Microdilution, time-kill, and postantifungal-effect studies. Antimicrob Agents Chemother 46: 3846-3853. https://doi.org/10.1128/AAC.46.12.3846-3853.2002.
38. Paderu P, Garcia-Effron G, Balashov S, Delmas G, Park S, Perlin DS. 2007. Serum differentially alters the anti-fungal properties of echinocandin drugs. Antimicrob Agents Chemother 51: 2253-2256. https://doi.org/10.1128/AAC.01536-06.
39. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard M27-A3. Clinical and Laboratory Standards Institute, Wayne, GA.